Ocular Therapeutix and AffaMed Therapeutics have entered an agreement for the development and commercialization of Dextenza and OTX-TIC in areas of Asia, according to a press release.
The agreement entitles Ocular Therapeutix to an upfront $12 million payment, milestone payments and clinical development support payments totaling up to $91 million, and royalties from future sales, the release said.
AffaMed receives the right to develop and market Dextenza (dexamethasone ophthalmic insert 0.4 mg), which is approved in the U.S. for postsurgical ocular inflammation and pain, and OTX-TIC (travoprost
Uncategorized